Brand VerifiedFrance

Ceva Santé Animale S.A.

Ceva

Ceva Santé Animale is one of the world's fastest-growing independent animal health companies, distinguished by its employee-and-PE consortium ownership structure and extraordinary manufacturing footprint. Founded in 1999 and headquartered in Libourne, France, Ceva generated approximately EUR 1.77 billion (~USD 1.9 billion) in 2024 revenue, employing 7,000 employees across 32 production sites and 21 R&D centers. Ceva's defining strength is its 12.8% capital expenditure-to-sales ratio—far above industry average—directing massive investment into vaccine fermentation, proprietary pheromone extraction, and in-ovo injection device manufacturing, with its landmark Monor, Hungary facility alone producing over 8 billion vaccine doses annually.

Strengths:
• Manufacturing Scale & Intensity: 32 owned production sites across 110+ countries—one of the industry's most extensive self-owned manufacturing networks—with 12.8% of revenue reinvested in capex
• Pheromone Niche Dominance: Proprietary Feliway and Adaptil pheromone products command near-monopoly positions in the global pet behavioral health market
• Vaccine Production Leadership: 54% of R&D budget allocated to vaccine development; Monor, Hungary facility produces 8+ billion doses annually of multi-component inactivated vaccines
• Strategic Gene Therapy Entry: 2025 acquisition of Scout Bio marks entry into companion animal gene therapy, positioning Ceva at the frontier of veterinary biotechnology
• Prestigious Shareholder Consortium: Backed by Temasek, Mérieux Institute, and ARCHIMED—providing virtually unlimited acquisition capital for strategic expansion
Weaknesses:
• Revenue Scale Gap: At ~$1.9B, Ceva remains significantly smaller than the Big Four (Zoetis, Merck, Boehringer, Elanco), limiting absolute R&D spend despite high percentage allocation
• Historical Livestock Concentration: Traditional strength in poultry and swine vaccines means the companion animal portfolio is still building depth relative to pure-play competitors
• Private Ownership Opacity: Limited public financial disclosure makes independent assessment of segment-level profitability and capacity utilization challenging

Business Nature

Ceva Santé Animale is a pure-play multinational animal health company that remains privately held by its management, employees, and a consortium of top-tier private equity investors including Temasek, Mérieux Institute, and ARCHIMED. The company's manufacturing footprint is among the most extensive in the industry, comprising 32 production sites and 21 R&D centers worldwide.

Ceva allocates 12.8% of annual sales to capital expenditure—substantially above industry average—directing funds into advanced vaccine fermentation, pheromone extraction, and in-ovo injection device manufacturing. Its landmark facility in Monor, Hungary 7,000 m² was purpose-built for multi-component inactivated vaccine mass production, with annual capacity exceeding 8 billion doses. Ceva acquired Scout Bio in 2025, entering the companion animal gene therapy space.

Core Business Areas

Companion Animal Portfolio — Core Business
• Pet Behavioral Health: Feliway / Adaptil pheromone products
• Vaccines: Feligen / Vanguard partnership products
• Anti-infectives & Parasiticides
• Reproduction & AI technologies
• Poultry and swine vaccines traditional strength

Industry Rankings

6Top 10 Veterinary Pharmaceuticals & Pet Healthcare Companies

Brand

6Top 10 Veterinary Pharmaceuticals & Pet Healthcare Manufacturers & Suppliers

Mfr

Corporate Report

Ceva Santé Animale is a France-based independent multinational animal health company headquartered in Libourne, Nouvelle-Aquitaine. Founded in 1999, Ceva has grown to become one of the world's largest privately-held animal health enterprises. In 2024, the company generated approximately EUR 1.77 billion (~USD 1.9 billion) in global revenue, employing 7,000 people across 32 production sites and 21 R&D centers in 110+ countries.

Core Business

Ceva's companion animal portfolio is anchored by its globally dominant pheromone-based behavioral health products—Feliway (feline calming pheromone) and Adaptil (canine appeasing pheromone)—which command near-monopoly positions in their respective categories. The company also maintains a significant vaccine portfolio, with 54% of its R&D budget dedicated to vaccine development. Its landmark 2025 acquisition of Scout Bio signals an ambitious entry into the companion animal gene therapy frontier.

Global Presence

Operating with 47 direct country-level offices and products in 110+ nations, Ceva's manufacturing network of 32 production sites is one of the industry's most extensive. The Monor, Hungary facility—a 7,000 m² purpose-built vaccine production plant—delivers over 8 billion doses annually of multi-component inactivated vaccines. In 2025, the company completed a landmark capital restructuring, maintaining management majority control while welcoming Temasek, Mérieux Institute, and ARCHIMED as strategic investors, providing capital firepower for continued global expansion.

Key Strengths

• 32 owned production sites across 110+ countries—one of the industry's most extensive self-owned manufacturing networks
• Proprietary Feliway and Adaptil pheromone products commanding near-monopoly pet behavioral health market positions
• Industry-leading 12.8% capex-to-revenue ratio fueling continuous capacity expansion
• 2025 Scout Bio acquisition positioning Ceva at the frontier of companion animal gene therapy
• Prestigious consortium backing (Temasek, Mérieux, ARCHIMED) providing unlimited strategic capital access

VerityRank Score

VerityRank Score of 89/100

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Libourne, Nouvelle-Aquitaine, France

Founded

1999

Employees

7,000

Factories

32 production sites globally

Listing

Private (employee + PE consortium)

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website , Ceva Official Website
Wikipedia — Ceva Santé Animale
Fitch Ratings — Ceva

Back to Rankings